Molecular Templates, Inc. (MTEM)
| Market Cap | 163.28M |
| Revenue (ttm) | 24.23M |
| Net Income (ttm) | -101.21M |
| Shares Out | 56.31M |
| EPS (ttm) | -1.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,040 |
| Open | 2.87 |
| Previous Close | 2.86 |
| Day's Range | 2.76 - 2.94 |
| 52-Week Range | 2.76 - 15.19 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 11.57 (+299.0%) |
| Earnings Date | n/a |
About MTEM
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TA...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for MTEM stock is "Strong Buy." The 12-month stock price forecast is 11.57, which is an increase of 298.97% from the latest price.
News
Molecular Templates Provides Corporate Update and Outlines 2022 Milestones
Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -68.75% and -84.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and devel...
Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.
Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 98.3% in Molecular Templates Inc. (MTEM). While the effectiveness of this highly sought-after metric is questiona...
Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?
Molecular Templates Inc. (MTEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...
Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -115.38% and -50.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and devel...
Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...
Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...
Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Canc...
Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a no...
Why Molecular Templates Stock Crashed Today
The company is taking back rights to one drug candidate and discontinuing development of another.
Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies
Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-...
Molecular Templates to Prioritize Next-Generation ETB Candidates
Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...
The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.
The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
Why Veru, Invitae And More Are Moving Today
Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospit...
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and developm...
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Developmen...
Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payment with po...
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin ...
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...